SAPIEN 3: Low One-Year-Mortality in High Risk or Inoperable Patients

sapien3In the first PARTNER trial (Placement of Aortic Transcatheter Valves), mortality at one year was 24% for high risk patients and 31% for inoperable patients. A recent report on SAPIEN 3 outcomes at 30 days ─ the last generation balloon expandable valve ─ showed a rather lower adverse events rate. However, additional information at longer term was required.

 

Between October 2013 and September 2014, 583 patients ─ 65% high risk and 35% inoperable ─ were treated with the new device via femoral access site (84%) or transapical/trans-aortic (16%) access site.

 

Population mean age was 83, with 8.4% STS score.

 

One year survival rate was 87.3% for the high risk group and 82.3% for the inoperable group.

 

There were no cases of severe paravalvular leak and those with moderate leaking (2.7%) showed higher mortality rate at one year. Low paravalvular leak had no significant association with mortality.

 

At multivariable analyzis, one year mortality predictors were:

  • Vascular access site other than femoral
  • STS score
  • Disabling stroke

 

Conclusion

This large study on the SAPIEN 3 valve in high risk or inoperable patients showed a very low complications rate that resulted in reduced mortality at one year.

 

Between days 30 and 365, paravalvular leak rate did not increase and there was no association between low paravalvular leak and mortality.

 

Original Title: One-Year Clinical Outcomes with SAPIEN 3 Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients with Severe Aortic Stenosis.

Reference: Howard C. Herrmann et al. Circulation. 2016;134:130–140.

 

We value your opinion. Feel free to leave your thoughts, comments, questions or suggestions here below. They will be more than welcome.

More articles by this author

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...

J-Valve for Chronic AR: 30-Day Outcomes of Transfemoral Valve J-Valve in Chronic Aortic Regurgitation

Chronic aortic regurgitation (AR) poses a significant challenge as far as transcatheter alternatives go due to the absence of calcification and a suitable anchoring...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...